Celyad Oncology SA Overview
Celyad Oncology is a Belgian former clinical-stage CAR-T cell therapy developer that has been reduced, through a series of restructurings between 2022 and 2026, to an intellectual-property holding and licensing shell. It pioneered NKG2D-receptor-based CAR-T cells (licensed from Dartmouth College via Celdara Medical) and non-gene-edited allogeneic approaches using T-cell receptor inhibitory molecules and short-hairpin RNA (shRNA), but discontinued clinical development in late 2022 and all R&D in August 2025. It sold its research facility (EUR 3M, 2025) and its legacy C-CATHez cardiac catheter to CellProthera (up to EUR 5M deferred plus royalties, February 2026). With roughly four employees, a treasury position of EUR 0.1M at 30 June 2026 topped up by a EUR 0.5M Fortress placement, and a market value near EUR 8M, Celyad's equity value now rests on monetising its CAR-T patent estate through out-licensing — under the effective control of Fortress Investment Group.
Company self-description
In its current boilerplate, Celyad describes itself as a biotechnology company focused primarily on unlocking the potential of its intellectual property, headquartered in Mont-Saint-Guibert (FY2025 release, 2 Apr 2026). The 2025 business highlights state that it remains focused on partnering its IP and has progressed discussions with potential partners for selected out-licensing of its technologies.
Independent characterisation
Celyad is no longer an operating biotech. It is a listed IP vehicle whose assets are (i) a CAR-T patent portfolio — NKG2D-based CARs, allogeneic platforms (TIM and shRNA), and related know-how — and (ii) contingent consideration from the C-CATHez sale. It has no product revenue, no clinical programmes, no laboratory, and a skeletal staff. Its cost base has been cut from ≈ EUR 30M per year (2021–2022 R&D plus G&A) to an H1 2026 operating loss of EUR 1.2M. Its survival depends on small, repeated equity injections from Fortress, which controls the company. Value realisation would come from: licence fees/milestones/royalties from third parties using its patents; milestone payments from CellProthera; or a corporate transaction (reverse merger/shell sale) leveraging the listing.
Revenue model
| Revenue type | FY2025 | Comment |
|---|---|---|
| Product sales | ≈0 | Residual EUR 21k revenue in FY2025 (cost of sales EUR 8k) — likely legacy catheter or service items |
| Licensing / royalties | 0 recognised | Target business model; no firm licence signed as of FY2025 (no change in fair value of Dartmouth/Celdara contingent liabilities) |
| Asset-sale consideration | Recognised in other income | Research-facility sale gain EUR 2.3M (2025); C-Cath gain (H1 2026) |
| Grants / R&D tax credits | Recognised in other income | Walloon Region grant income and R&D tax-credit derecognition gains (2025) |
Value-chain position and customers
Upstream IP originator/licensor in cell therapy. Prospective counterparties are CAR-T and cell-therapy developers (pharma and biotech) that may need freedom-to-operate under Celyad's NKG2D or allogeneic patents, plus CellProthera for the catheter. End-markets: oncology cell therapy (haematological and solid tumours) and, via the catheter, cardiac regenerative medicine.
Strategy
Stated strategy
-
Partner and out-license the IP portfolio; selective out-licensing discussions reported as progressing (FY2025 release).
-
Run the company at minimal cost after discontinuing R&D and selling physical assets (Aug 2025 release: intends to sell remaining assets to focus on IP).
-
Maintain listing and continuity — the board proposed continuation under the Belgian "alarm bell" procedure (Art. 7:228 BCCA) at the 20 May 2026 AGM.
Initiatives in the last 24 months
| Date | Initiative | Detail | Status |
|---|---|---|---|
| 24 Jun 2025 | Strategic review | Asset sales, restructuring, M&A, financing all considered | Executed via asset sales and restructuring |
| 29 Jul 2025 | EUR 1M Fortress placement | Bridge funding | Closed |
| 25 Aug 2025 | R&D discontinuation | Significant workforce reduction | Completed |
| 30 Sep 2025 | Research facility sale | EUR 3M; gain EUR 2.3M | Completed |
| 2,025 | Termination of Walloon-subsidised research contracts | Research results transferred to Region; RCAs reduced | Completed |
| 12 Feb 2026 | C-CATHez sale to CellProthera | Up to EUR 5M milestones + royalties | Completed; gain booked H1 2026 |
| 14–16 Jul 2026 | EUR 0.5M Fortress placement | Runway extended from Q3 2026 to ≈ mid-Q2 2027 | Closed |
Guidance
No financial targets. Cash runway guidance: "until 2027" (H1 2026 release); press reporting of the July placement cites ≈ mid-Q2 2027.
Products & Services
Celyad has no marketed products. Its "portfolio" consists of IP assets and discontinued programmes.
Pricing model: licensing terms not disclosed.
Product Portfolio
| Asset | Type | Description | Status | Notes |
|---|---|---|---|---|
NKG2D CAR-T IP | Patent family | CAR constructs using the NKG2D receptor to target NKG2D ligands on tumour cells; in-licensed from Dartmouth via Celdara (OnCyte acquisition) | Available for out-licensing | Contingent consideration owed to Dartmouth/Celdara on sublicensing |
Allogeneic TIM platform | Patent family / know-how | Non-gene-edited allogeneic CAR-T using a T-cell receptor inhibitory molecule (basis of CYAD-101) | Development discontinued | — |
shRNA allogeneic platform | Licensed platform / patents | All-in-one vector shRNA to knock down TCR/other targets (Horizon Discovery SMARTvir), basis of CYAD-200 series incl. CYAD-211 (BCMA) | Discontinued; intangible fully impaired in 2022 | Impairment EUR 35.1M (2022) |
CYAD-01 / CYAD-02 | Autologous NKG2D CAR-T candidates | Clinical programmes in AML/MDS | Discontinued | — |
CYAD-101 | Allogeneic NKG2D CAR-T | Colorectal cancer programme | Halted (2022) | — |
CYAD-211 | Allogeneic anti-BCMA shRNA CAR-T | Multiple myeloma | Discontinued late 2022 | Dealroom |
C-CATHez | Transendocardial injection catheter | Delivers cells directly into damaged myocardium | Sold to CellProthera, Feb 2026 (up to EUR 5M + royalties) | Gain recognised H1 2026 |
Walloon Region-funded research results | Research IP | Results of subsidised contracts | Rights transferred to the Walloon Region in 2025 | Generated grant income |
Financial Narrative
Income statement
Sources: FY2022 release (FY2021–FY2022 columns), FY2023 release, FY2025 release (FY2024–FY2025 IFRS statements). FY2023 R&D/G&A/other income lines were not captured from primary sources. Revenue "–" in the FY2022 release is shown as 0. Margins are not meaningful given negligible revenue. EBITDA is not reported; an aggregator (Parqet) shows FY2025 EBITDA of −EUR 3.58M.
Commentary. The trajectory is one of deliberate shrinkage. In 2021–2022 Celyad ran a ≈ EUR 30M annual R&D+G&A cost base. FY2022's loss was inflated by a EUR 35.1M impairment (partly offset by a EUR 14.7M reversal of contingent consideration) when clinical programmes were stopped. FY2023 losses fell to EUR 8.5M under "Celyad 2.0." By FY2024 combined R&D and G&A were ≈ EUR 6.4M. FY2025's reported net profit of EUR 0.83M is entirely non-recurring: other income of EUR 8.26M came from (i) grant income recognised when Celyad ended Walloon-subsidised research contracts and transferred results to the Region, (ii) R&D tax-credit liability derecognition, and (iii) a EUR 2.3M gain on the research facility sale. Underlying costs actually rose in 2025 (R&D +EUR 0.2M; G&A +EUR 0.6M) because of severance. H1 2026 operating loss was EUR 1.2M (vs EUR 3.7M in H1 2025), reflecting the new minimal cost base and a C-Cath sale gain.
Balance sheet
Source: FY2025 consolidated statement of financial position (FY2024–FY2025); treasury FY2021–FY2022 from FY2022 release. FY2025 includes assets held for sale EUR 0.682M (C-Cath) and liabilities held for sale EUR 0.100M. A "capital reduction reserve" of EUR 320.7M offsets historical losses. Recoverable cash advances (RCAs) are Walloon Region funding repayable on commercial success — debt-like; the large reduction in 2025 reflects the transfer of research rights to the Region.
Net debt (FY2025, derived): RCAs EUR 0.621M − cash EUR 1.708M = net cash EUR 1.09M.
Interim: Cash at 30 Jun 2025 EUR 0.8M; at 30 Jun 2026 EUR 0.1M (H1 2026 release).
Cash flow: notes and sources
Sources: FY2022, FY2023, FY2025 releases. Note an inconsistency inside the FY2025 release: the headline table labels the EUR 2.5M/2.8M net cash burn as "net cash used in operations," while the text and cash table give EUR 6.9M/5.7M as net cash used in operations. The cash table values are used here. Financing in 2025 includes the EUR 1M Fortress placement; investing includes the EUR 3M facility sale. H1 2026 operating cash use: EUR 1.5M (vs EUR 3.3M in H1 2025).
Ratios
FY2025 ROE/ROA on closing balances (derived) and driven by one-off gains — not meaningful as indicators of earning power. ROIC, net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle are not meaningful for a pre-revenue IP shell.
Interim trend
Sources: H1 2025 release; H1 2026 coverage (Fortuneo, ABC Bourse, Idéal Investisseur). One source gives H1 2025 net loss as EUR 3.3M and EPS −EUR 0.09; the company's H1 2025 release gives EUR 3.7M — minor discrepancy noted; EUR 3.7M used.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment and Revenue by Segment (%)
| Segment metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Single segment revenue (EUR Mn) | — | 0.186 | 0.021 |
Single segment operating profit (EUR Mn) | -8.5 | -5.858 | 0.881 |
Share of total revenue (%) | 100 | 100 | 100 |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (EUR Mn) | 0 | 0 | — | 0.186 | 0.021 |
Gross profit (EUR Mn) | — | — | — | 0.173 | 0.013 |
R&D expenses (EUR Mn) | 20.8 | 18.9 | — | 3.235 | 3.416 |
G&A expenses (EUR Mn) | 9.9 | 10.5 | — | 3.198 | 3.779 |
Change in fair value of contingent consideration (EUR Mn) | 0.8 | 14.7 | — | 0 | 0 |
Impairment of oncology intangibles (EUR Mn) | 0 | -35.1 | 0 | 0 | 0 |
Other income/(expenses) net (EUR Mn) | 3.4 | 9.0 | — | 0.401 | 8.063 |
Operating profit/(loss) (EUR Mn) | -26.4 | -40.9 | -8.5 | -5.858 | 0.881 |
Pre-tax profit/(loss) (EUR Mn) | — | — | — | -5.824 | 0.830 |
Net profit/(loss) (EUR Mn) | -26.5 | -40.9 | -8.5 | -5.824 | 0.830 |
EPS basic = diluted (EUR) | -1.70 | -1.81 | -0.33 | -0.14 | 0.018 |
Dividend per share (EUR) | 0 | 0 | 0 | 0 | 0 |
Balance Sheet
| Metric | FY2021 | FY2022 | FY2024 | FY2025 |
|---|---|---|---|---|
Total assets (EUR Mn) | — | — | 9.928 | 4.298 |
Cash & equivalents (EUR Mn) | — | 12.4 | 4.200 | 1.708 |
Treasury position incl. short-term investments (EUR Mn) | 30.0 | 12.4 | 4.2 | 1.7 |
Lease liabilities total (EUR Mn) | — | — | 0.905 | 0 |
Recoverable cash advances total (EUR Mn) | — | — | 4.834 | 0.621 |
Equity (EUR Mn) | — | — | 0.511 | 2.436 |
Goodwill & intangibles (EUR Mn) | — | — | 0.405 | 0.016 |
Working capital – current assets less current liabilities (EUR Mn) | — | — | 3.669 | 1.679 |
Accumulated deficit (EUR Mn) | — | — | -364.196 | -363.366 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Net cash used in operations (EUR Mn) | -26.6 | -28.0 | -15.2 | -5.680 | -6.900 |
Net cash from/(used in) investing (EUR Mn) | — | — | — | -0.103 | 3.007 |
Net cash from financing (EUR Mn) | — | — | — | 2.983 | 1.394 |
Net cash burn – change in treasury (EUR Mn) | — | — | — | -2.800 | -2.499 |
Dividends paid (EUR Mn) | 0 | 0 | 0 | 0 | 0 |
Buybacks (EUR Mn) | 0 | 0 | 0 | 0 | 0 |
Financial Ratios (x) and Returns & Leverage Ratios (%)
| Ratio | FY2024 | FY2025 |
|---|---|---|
Current ratio (x, derived) | 2.29 | 1.92 |
Equity / total assets (%) | 5.1 | 56.7 |
ROE (%) | — | 34.1 |
ROA (%) | — | 8.4 |
Cash Flow and Per-Share Data
| Metric | H1 2024 | H1 2025 | H1 2026 |
|---|---|---|---|
Net profit/(loss) (EUR Mn) | -3.0 | -3.7 | -1.2 |
Net cash used in operations (EUR Mn) | -2.8 | -3.3 | -1.5 |
Cash & equivalents at period end (EUR Mn) | 6.2 | 0.8 | 0.1 |
EPS (EUR) | — | -0.09 | -0.027 |
Share Price & Returns
| Reference point | Price | Source |
|---|---|---|
16 Oct 2026 (Frankfurt) | EUR 0.174 | finanznachrichten.de |
~Jul 2026 (placement reference) | ≈ EUR 0.235 (10-day VWAP implied by EUR 0.20 at 15% discount, derived) | Company release |
12 Jun 2026 | USD 0.30 | PitchBook |
Dec 2021 (Fortress placement) | USD 5.00 per share | Company release |
Performance | Value | — |
5-year | ≈ −96% from the USD 5.00 placement price (Dec 2021) to ≈ EUR 0.17 (derived, approximate FX) | — |
Valuation Snapshot
| Multiple | Value |
|---|---|
Market cap (derived) | ≈ EUR 8M |
P/E | Not meaningful (one-off profit) |
EV/EBITDA | Not meaningful (negative EBITDA) |
P/B (FY2025 equity EUR 2.44M) | ≈ 3.4x (derived) |
Analyst Conclusions
Guidance
No operating guidance. Cash runway "until 2027" after the July 2026 EUR 0.5M placement (H1 2026 release); press coverage of the placement cites extension to ≈ mid-Q2 2027. No consensus estimates exist.
Bull case
-
Licensing optionality at a tiny valuation: a single licence fee in the low single-digit EUR millions would be material against an ≈ EUR 8M market value and ≈ EUR 2–3M annual cost base.
-
CellProthera milestones: up to EUR 5M deferred consideration plus royalties if the Phase 3 catheter-enabled therapy progresses.
-
Shell value: a listed Euronext vehicle with Fortress control could be used for a reverse merger, creating value for remaining holders.
Bear case
-
Perpetual dilution: each funding round (latest at EUR 0.20) erodes minority value; Fortress's voting control grows.
-
No proven IP demand: no licence signed despite two years of IP-focused strategy; contingent payments to Dartmouth/Celdara reduce net economics.
-
Going-concern and liquidation risk: cash of EUR 0.1M at mid-2026 and an auditor material-uncertainty paragraph mean survival depends entirely on Fortress.
Catalysts and monitorables (next 12 months)
-
Any out-licensing agreement or patent-assertion action.
-
CellProthera Phase 3 start (milestone triggers).
-
Further Fortress placements, or a squeeze-out/delisting proposal.
-
Outcome of any reverse-merger or strategic transaction.
-
FY2026 results (≈ April 2027) and auditor going-concern opinion.
-
Tolefi stance (transparency notification of 28 Jul 2026; supermajority rights).
Analyst verdict
Celyad Oncology is a cautionary arc in European biotech: from a Nasdaq-listed CAR-T pioneer that raised a USD 100M US IPO and a USD 32.5M premium placement from Fortress in December 2021, to a four-person IP shell holding EUR 0.1M of cash in June 2026. The decline was driven by clinical setbacks, a EUR 35.1M write-off of its allogeneic and shRNA assets in 2022, and a funding environment that left no room for a sub-scale cell-therapy developer. Management has since done what was necessary: discontinued R&D, sold the laboratory for EUR 3M, monetised the legacy C-CATHez catheter for up to EUR 5M in deferred consideration, ended subsidised research contracts (unwinding most recoverable cash advances), and cut the cash burn to roughly EUR 3M a year.
The FY2025 "profit" should be ignored as an earnings signal — it is entirely the product of one-off grant recognition, tax-credit derecognition and asset-sale gains. The relevant questions are whether the NKG2D and allogeneic patent estate has commercial read-through to products that others are developing, and whether Fortress intends to keep the vehicle alive long enough to find out. Fortress's willingness to fund EUR 0.5M at a discount in July 2026 suggests it sees residual value — but its terms also concentrate control (≈ 68.8% of votes) and dilute minorities.
For outside shareholders, Celyad is best viewed as a binary, option-like micro-cap with a material probability of further dilution and a non-trivial probability of eventual delisting or liquidation. Upside exists from a licence deal, CellProthera milestones, or a shell transaction, but none is visible or contracted. We would not regard the equity as investable on fundamentals; it is suitable only for speculative capital that accepts total-loss risk and minimal governance leverage against a controlling shareholder.
Sources consulted
-
Celyad FY2025 results release, 2 Apr 2026: https://www.finanznachrichten.de/nachrichten-2026-04/68117430-celyad-oncology-reports-full-year-2025-financial-results-and-business-highlights-004.htm
-
Celyad H1 2026 results coverage: https://www.abcbourse.com/marches/celyad-oncology-reduit-sa-perte-au-premier-semestre-2026-et-renforce-sa-tresorer_703030 ; https://bourse.fortuneo.fr/actualites-amp/celyad-oncology-limite-sa-perte-au-1er-semestre-8015283 ; https://www.ideal-investisseur.fr/en/stock-news/celyad-oncology-cash-position-reduced-to-eur0-1m-and-losses-decreased-in-first-half-2026/25690.html
-
Celyad H1 2025 results: https://www.1stoncology.com/blog/?p=105732
-
C-CATHez sale release, 12 Feb 2026: https://www.vfb.be/Media/Default/pdf/CCath-sale-PR-Celyad.Feb2026.ENG_.2.pdf
-
R&D discontinuation, Aug 2025: https://www.businesswire.com/news/home/20250825896161/en/Celyad-Oncology-Announces-Discontinuation-of-RD-Activities
-
Strategic review, Jun 2025: https://www.businesswire.com/news/home/20250624889093/en
-
EUR 0.5M placement, Jul 2026: https://www.1stoncology.com/blog/?p=112233 ; https://bourse.fortuneo.fr/actualites/celyad-un-placement-prive-de-500-000-euros-5690443
-
Euronext press-release list: https://live.euronext.com/en/listview/company-press-release/198995
-
Bourse Direct news archive: https://www.boursedirect.fr/en/news/value/celyad-oncology-sa-BE0974260896-CYAD-EUR-XBRU
-
FY2023 results: https://www.businesswire.com/news/home/20240403848637/en/Celyad-Oncology-Reports-Full-Year-2023-Financial-Results-and-Recent-Business-Highlights
-
FY2022 results: https://www.1stoncology.com/blog/?p=85372
-
Fortress USD 32.5M placement, Dec 2021: https://flanders.bio/en/news/celyad-oncology-private-placement-fortress-investment-group
-
EUR 9.8M commitments, Aug 2023 (SEC 6-K): https://www.sec.gov/Archives/edgar/data/1637890/000119312523220581/d543442dex991.htm
-
FSMA prospectus summary, Feb 2022: https://www.fsma.be/sites/default/files/prospectus/files/2022/SMRY-20220702-EN-DOCREG-2022-000024-03.pdf
-
financialfilings.com company page: https://www.financialfilings.com/companies/celyad-oncology-sa/
-
PitchBook profile (aggregator): https://pitchbook.com/profiles/company/56851-48
-
Dealroom profile (aggregator): https://dealroom.co/companies/celyad-oncology/
-
Parqet profile (aggregator): https://app.parqet.com/wertpapiere/BE0974260896
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Notes |
|---|---|---|---|
Hannes Iserentant | General Manager; investor/media contact | At least since Apr 2026 | Named on FY2025 release as General Manager |
Matt Kane | Chief Executive Officer (as of Aug 2025) | — | Quoted in R&D discontinuation release (Aug 2025); current status not confirmed — FY2025 release lists only a General Manager as contact, suggesting possible departure |
David Georges | Contact named on 2025 releases (role not specified; possibly finance/IR) | — | Business Wire contact block |
Executive Leadership Team by Director
| Director | Role | Affiliation | Notes |
|---|---|---|---|
Fortress-nominated directors (affiliate represented by Michel Lussier, co-opted 2023) | Non-executive | Fortress Investment Group | Fortress has had the right to nominate two directors while holding ≥10% (2021 rights agreement); did not vote on July 2026 related-party placement |
Tolefi-nominated director | Non-executive | Tolefi SA | Right to one seat while holding ≥5% (2023 agreement) |
Independent directors (names not captured) | Non-executive | Independent | Formed the Art. 7:97 committee approving the July 2026 placement |
Major Shareholders
| Holder | % shares | % voting rights | Date / Source |
|---|---|---|---|
CFIP CLYD (UK) Ltd / Fortress Investment Group | ≈ 60.5–60.7 | ≈ 68.75–68.84 | Post 16 Jul 2026 placement (company release; Investing.com) |
Tolefi SA | Not disclosed post-dilution | — | Transparency notification published 28 Jul 2026 (content not captured); ≈16% after Sep 2023 tranche, diluted thereafter |
Free float / others | ≈ 25–30 (derived) | — | Derived |
“—” = not publicly disclosed.
Competitive Landscape
Competitors by Segment
| Area | Company | Positioning relative to Celyad |
|---|---|---|
Autologous CAR-T (approved products) | Novartis | Kymriah; potential licensee/historical licensee |
Autologous CAR-T | Gilead/Kite | Yescarta, Tecartus |
Autologous CAR-T | Bristol Myers Squibb | Breyanzi, Abecma |
Autologous CAR-T | Johnson & Johnson / Legend Biotech | Carvykti (BCMA) |
Allogeneic CAR-T | Allogene Therapeutics | Gene-edited allogeneic leader |
Allogeneic CAR-T | Cellectis | TALEN-edited allogeneic; IP-heavy French peer |
Allogeneic CAR-T | Caribou Biosciences | CRISPR-edited allogeneic |
NKG2D-based cell therapy | Nkarta | NKG2D-CAR NK cells — closest technology overlap |
Allogeneic/in vivo CAR | CRISPR Therapeutics | Gene-edited allogeneic programmes |
IP-licensing shells | Various | Compete for licensee attention |
Benchmark | Celyad FY2025 | Peers |
Revenue | EUR 0.021M | — |
R&D intensity | N/M | — |
Margins | N/M | — |



